Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iotroxate meglumine, quantity: 105.46 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; sodium bicarbonate; sodium chloride; water for injections - biliscopin for infusion is indicated for radiological examination of hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine iotroxate 105 mg/ml equivalent to to 50 mg/ml iodine - solution for infusion - 105 mg/ml - active: meglumine iotroxate 105 mg/ml equivalent to to 50 mg/ml iodine excipient: sodium bicarbonate sodium chloride sodium edetate water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

meglumine iotroxate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine iotroxate - solution for infusion - 50mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - iotroxate meglumine - 20 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - iotroxate meglumine - 30 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - iotroxate meglumine - solution for infusion - 100 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - iotroxate meglumine - solution for infusion - 250 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - iotroxate meglumine - solution for infusion - 105 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.